LEO LUZNIK to Histocompatibility Testing
This is a "connection" page, showing publications LEO LUZNIK has written about Histocompatibility Testing.
Connection Strength
1.691
-
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016 Jan; 13(1):10-24.
Score: 0.485
-
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biol Blood Marrow Transplant. 2018 10; 24(10):2056-2064.
Score: 0.147
-
Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 05; 102(5):932-940.
Score: 0.134
-
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 02; 102(2):391-400.
Score: 0.131
-
Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Semin Hematol. 2015 Jul; 52(3):232-42.
Score: 0.118
-
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11; 124(25):3817-27.
Score: 0.114
-
Are alternative donors really still "alternative?". Biol Blood Marrow Transplant. 2014 Oct; 20(10):1463-4.
Score: 0.113
-
Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun; 43(12):969-70.
Score: 0.077
-
Nonmyeloablative alternative donor transplants. Curr Opin Oncol. 2003 Mar; 15(2):121-6.
Score: 0.051
-
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020; 11:636.
Score: 0.042
-
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016 Apr 12; 9:35.
Score: 0.032
-
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
Score: 0.031
-
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2115-2122.
Score: 0.030
-
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
Score: 0.030
-
Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol. 2014 Sep; 93(3):187-97.
Score: 0.028
-
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013 Apr; 19(4):602-6.
Score: 0.025
-
Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant. 2013 Apr; 19(4):647-52.
Score: 0.025
-
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
Score: 0.025
-
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013 Mar; 54(3):655-7.
Score: 0.025
-
Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct; 42(8):523-7.
Score: 0.018
-
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8(7):377-86.
Score: 0.012